CNMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Conmed Corp (CNMD) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks positive catalysts, has bearish technical indicators, and recent financial performance shows significant declines in net income and EPS. Analysts have downgraded the stock, citing execution missteps and lack of identifiable catalysts. While the stock may stabilize over time, it does not currently present a compelling entry point.
The technical indicators for CNMD are bearish. The MACD histogram is below 0 and negatively contracting, the RSI is neutral at 37.312, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels indicate the stock is closer to its support (S1: 33.818) than its resistance (R1: 37.088).
The company's gross margin increased by 2.02% YoY in Q4 2025, indicating some operational efficiency improvements.
The stock has been downgraded by analysts, citing execution missteps and lack of catalysts. Net income and EPS dropped significantly in the latest quarter. Additionally, the stock has a 60% chance of declining further in the short term based on historical patterns.
In Q4 2025, revenue increased by 7.88% YoY to $373.2M. However, net income dropped by -50.41% YoY to $16.7M, and EPS decreased by -50.00% YoY to 0.54. Gross margin improved slightly to 58.49%.
Recent analyst ratings are neutral to negative. Wells Fargo maintained an Equal Weight rating with a $42 price target, while Piper Sandler downgraded the stock to Neutral from Overweight, lowering the price target to $39 from $55, citing lack of catalysts and execution missteps.
